R.M. Sincerbeaux Capital Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-2,930
Closed -$235K 50
2019
Q3
$235K Hold
2,930
0.19% 47
2019
Q2
$234K Sell
2,930
-2,096
-42% -$160K 0.19% 45
2019
Q1
$399K Hold
5,026
0.32% 41
2018
Q4
$366K Hold
5,026
0.34% 40
2018
Q3
$340K Hold
5,026
0.28% 45
2018
Q2
$291K Sell
5,026
-2,096
-29% -$118K 0.26% 49
2018
Q1
$370K Hold
7,122
0.35% 40
2017
Q4
$382K Hold
7,122
0.35% 40
2017
Q3
$435K Sell
7,122
-3,144
-31% -$191K 0.42% 38
2017
Q2
$628K Hold
10,266
0.57% 37
2017
Q1
$622K Hold
10,266
0.58% 36
2016
Q4
$577K Hold
10,266
0.55% 36
2016
Q3
$611K Hold
10,266
0.6% 36
2016
Q2
$564K Hold
10,266
0.58% 38
2016
Q1
$518K Hold
10,266
0.54% 39
2015
Q4
$517K Hold
10,266
0.56% 39
2015
Q3
$484K Hold
10,266
0.51% 39
2015
Q2
$558K Hold
10,266
0.54% 37
2015
Q1
$563K Sell
10,266
-419
-4% -$23.7K 0.51% 38
2014
Q4
$579K Hold
10,685
0.53% 38
2014
Q3
$604K Hold
10,685
0.55% 39
2014
Q2
$590K Hold
10,685
0.55% 41
2014
Q1
$579K Hold
10,685
0.57% 39
2013
Q4
$510K Buy
+10,685
New +$488K 0.5% 43

Other funds holding MRK

R.M. Sincerbeaux Capital Management's MRK Position: Q4 2019 in Review

R.M. Sincerbeaux Capital Management sold out of Merck (MRK) in Q4 2019, closing a stake of 2,930 shares — an estimated $235K sold.

R.M. Sincerbeaux Capital Management first reported a position in MRK in Q4 2013 and held it in 24 quarters. The position peaked at $628K in Q2 2017. 2,537 funds tracked by Wall St. Rank hold MRK as of Q4 2019.

  • R.M. Sincerbeaux Capital Management reported no remaining Merck position as of Q4 2019 after selling out during the quarter.
  • R.M. Sincerbeaux Capital Management sold 2,930 Merck shares in Q4 2019, an estimated $235K.
  • R.M. Sincerbeaux Capital Management first reported a position in Merck in Q4 2013 and held it in 24 quarters.
  • R.M. Sincerbeaux Capital Management's Merck position peaked at $628K in Q2 2017.
  • 2,537 funds tracked by Wall St. Rank held Merck as of Q4 2019.

Based on R.M. Sincerbeaux Capital Management's 13F filing for Q4 2019, filed 6 Feb 2020.